New Cholesterol-Lowering drug HRS-1301 enters Mid-Stage trial

NCT ID NCT07229937

Recruiting now Disease control Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called HRS-1301 in people with high cholesterol (dyslipidemia). About 189 participants will receive one of four doses of HRS-1301 or a placebo daily for 12 weeks. The main goal is to see how much the drug lowers 'bad' LDL cholesterol and to find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-1301 (an experimental oral drug to lower cholesterol)
What this could lead to: If successful, this could provide a new treatment option for managing high cholesterol and reducing heart disease risk.
What could go wrong: This is an early Phase 2 trial with only 189 participants, so results may not apply to everyone. The drug may not work better than existing treatments or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperlipidemia inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERLIPIDEMIA

Contacts and locations

Locations

The 2nd Affiliated Hospital of Harbin
RECRUITING

Harbin, Heilongjiang, 150086, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.